

# CITATION REPORT

List of articles citing

**Mechanism of oligonucleotide uptake by cells:  
involvement of specific receptors?**

**DOI: 10.1073/pnas.86.17.6454**

**Proceedings of the National Academy of Sciences of  
the United States of America, 1989, 86, 6454-8.**

**Source:** <https://exaly.com/paper-pdf/20918355/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
483	Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates. <i>Nucleic Acids Research</i> , <b>1990</b> , 18, 3777-83	20.1	131
482	Molecular targets for AIDS therapy. <b>1990</b> , 249, 1533-44		692
481	Innovations in the use of antisense oligonucleotides. <b>1990</b> , 616, 161-72		8
480	Mechanisms for the control of gene activity during development. <b>1990</b> , 65, 431-71		109
479	Sequence-selective DNA recognition by synthetic ligands. <i>Bioconjugate Chemistry</i> , <b>1991</b> , 2, 1-12	6.3	94
478	Cellular uptake of phosphonylmethoxyalkylpurine derivatives. <b>1991</b> , 16, 115-9		66
477	Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. <b>1991</b> , 1, 161-71		87
476	Cell growth stimulation by EGF: inhibition through antisense-oligodeoxynucleotides demonstrates important role of casein kinase II. <b>1991</b> , 197, 245-53		85
475	Antisense Oligonucleotides as Pharmacological Modulators of Gene Expression. <i>Handbook of Experimental Pharmacology</i> , <b>1991</b> , 329-354	3.2	1
474	An Indexed Bibliography of Antisense Literature, 1978-1990. <b>1991</b> , 1, 65-113		11
473	In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide. <b>1991</b> , 1, 343-50		56
472	Antisense inhibition of beta-glucuronidase expression in preimplantation mouse embryos: a comparison of transgenes and oligodeoxynucleotides. <b>1991</b> , 1, 1-10		11
471	Non-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. <b>1991</b> , 1, 329-42		42
470	Chemisch modifizierte Oligonucleotide als Sonden und Agentien. <b>1991</b> , 103, 629-646		40
469	Reactive oligonucleotide derivatives as gene-targeted biologically active compounds and affinity probes. <b>1991</b> , 85, 53-63		7
468	Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. <i>Nucleic Acids Research</i> , <b>1991</b> , 19, 5543-50	20.1	167
467	Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages. <i>Nucleic Acids Research</i> , <b>1991</b> , 19, 1805-10	20.1	46

466	Intracellular distribution of microinjected antisense oligonucleotides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 2702-6	11.5	344
465	Nuclear Accumulation of Microinjected Antisense Oligonucleotides. <b>1991</b> , 10, 537-539		5
464	Oligonucleoside methylphosphonates as antisense reagents. <b>1991</b> , 9, 358-62		76
463	Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). <i>Nucleic Acids Research</i> , <b>1991</b> , 19, 5551-9	20.1	137
462	Antisense agents in cancer research and therapeutics. <b>1991</b> , 9, 185-94		40
461	Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. <b>1992</b> , 2, 211-22		138
460	Cell membranes as barriers for antisense constructions. <b>1992</b> , 2, 177-84		34
459	Liposomes as a drug delivery system for antisense oligonucleotides. <b>1992</b> , 2, 165-76		84
458	DNA binding to mouse cells is mediated by cell-surface molecules: the role of these DNA-binding molecules as target antigens in murine lupus. <b>1992</b> , 1, 167-73		23
457	In vivo stability and kinetics of absorption and disposition of 3Pphosphopropyl amine oligonucleotides. <i>Nucleic Acids Research</i> , <b>1992</b> , 20, 307-14	20.1	117
456	Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. <i>Nucleic Acids Research</i> , <b>1992</b> , 20, 5691-8	20.1	175
455	Drug targeting: synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates. <i>Nucleic Acids Research</i> , <b>1992</b> , 20, 4621-9	20.1	84
454	Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than With Azidothymidine. <b>1992</b> , 152, 485		8
453	Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. <b>1992</b> , 2, 17-25		87
452	Inhibition of murine leukemia viruses by nuclease-resistant alpha-oligonucleotides. <b>1992</b> , 2, 315-24		21
451	Anti-histone reactivity in systemic lupus erythematosus sera: a disease activity index linked to the presence of DNA:anti-DNA immune complexes. <b>1992</b> , 12, 61-8		8
450	Selective anti-gene therapy for cancer: principles and prospects. <b>1992</b> , 168, 351-9		6
449	Uses of antisense nucleic acids--an introduction. <b>1992</b> , 20, 745-6		11

448	Methylphosphonodiester/phosphodiester chimeric oligodeoxynucleotides. <b>1992</b> , 20, 746-9	7
447	Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible. <b>1992</b> , 2, 223-33	24
446	The detection of oligodeoxynucleotide molecules following uptake into mammalian cells. <b>1992</b> , 2, 119-27	15
445	Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells. <b>1992</b> , 2, 27-39	47
444	Lipofectin enhances cellular uptake of antisense DNA while inhibiting tumor cell growth. <b>1992</b> , 2, 51-9	21
443	Oligodeoxynucleotides as antisense inhibitors of gene expression. <b>1992</b> , 42, 79-126	68
442	Nucleosomes and DNA bind to specific cell-surface molecules on murine cells and induce cytokine production. <b>1992</b> , 63, 245-51	99
441	Antisense inhibitors of HIV: problems and perspectives. <b>1992</b> , 17, 279-87	17
440	Specific inhibition of oncogene expression in vitro and in vivo by antisense oligonucleotides. <b>1992</b> , 660, 37-44	8
439	Mechanistic aspects of the interaction of polyanionic oligodeoxynucleotides with HL60 cells. <b>1992</b> , 660, 313-4	1
438	Applications of antisense oligodeoxynucleotides in immunology and autoimmunity research. <b>1992</b> , 1, 191-202	10
437	Inhibition of cell adhesion to plastic substratum by phosphorothioate oligonucleotide. <b>1992</b> , 202, 391-7	19
436	Targeted delivery of antisense oligonucleotides by molecular conjugates. <b>1992</b> , 18, 559-69	45
435	Antisense c-myc oligodeoxyribonucleotide cellular uptake. <b>1992</b> , 9, 1010-7	56
434	Therapeutic implications of antisense oligonucleotides. <b>1992</b> , 21, 296-9	8
433	Poly(hydroxyfettsäureester), eine fünfte Klasse von physiologisch bedeutsamen organischen Biopolymeren?. <b>1993</b> , 105, 483-509	88
432	A General Method for the Synthesis of 2'-O-Modified Ribonucleosides. <b>1993</b> , 76, 884-892	19
431	Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit gene expression in primary embryonic neurons. <b>1993</b> , 14, 296-304	25

430	Antisense of oligonucleotides and the inhibition of oncogene expression. <b>1993</b> , 5, 245-52		11
429	Characteristics of oligonucleotide uptake in human keratinocyte cultures. <b>1993</b> , 101, 727-31		68
428	Modulation of human prorenin gene expression by antisense oligonucleotides in transfected CHO cells. <b>1993</b> , 212, 347-54		19
427	Antisense oligonucleotides as therapeutic agents--is the bullet really magical?. <b>1993</b> , 261, 1004-12		1316
426	Penetration of oligonucleotides into mouse organism through mucosa and skin. <b>1993</b> , 327, 271-4		21
425	As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells. <b>1993</b> , 3, 235-41		58
424	Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. <b>1993</b> , 32, 4855-61		155
423	Modification of antisense phosphodiester oligodeoxynucleotides by a 5Pcholesteryl moiety increases cellular association and improves efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1993</b> , 90, 1048-52	11.5	196
422	Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. <b>1993</b> , 161, 223-6		147
421	Use of Cationic Lipids to Enhance the Biological Activity of Antisense Oligonucleotides. <b>1993</b> , 3, 85-102		33
420	Antisense Nucleic Acids IProspects for Antiviral Intervention. <b>1993</b> , 4, 193-200		17
419	Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. <b>1993</b> , 259, 528-31		513
418	Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. <b>1993</b> , 3, 53-66		206
417	Imperfectly matched nucleic acid complexes and their biochemical manifestation. <b>1993</b> , 62, 387-407		3
416	Differential distribution of oligodeoxynucleotides in developing organs with epithelial-mesenchymal interactions. <i>Nucleic Acids Research</i> , <b>1993</b> , 21, 4961-6	20.1	7
415	Inhibition of gene transcription by purine rich triplex forming oligodeoxyribonucleotides. <i>Nucleic Acids Research</i> , <b>1993</b> , 21, 2845-52	20.1	48
414	Synthesis and hybridization properties of oligonucleotides containing 2PO-modified ribonucleotides. <i>Nucleic Acids Research</i> , <b>1993</b> , 21, 4499-505	20.1	27
413	Cell delivery and mechanisms of action of antisense oligonucleotides. <b>1993</b> , 44, 143-66		45

412	Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. <b>1993</b> , 3, 19-31		73
411	Internalization of oligodeoxyribonucleotides by <i>Vibrio parahaemolyticus</i> . <b>1993</b> , 3, 367-81		10
410	Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. <b>1993</b> , 3, 323-38		45
409	Patterns of cellular uptake and effects on cell survival using antimetallothionein oligodeoxyribonucleotide conjugates in vitro. <b>1994</b> , 3, 140-9		2
408	The role of the 5' untranslated region of eukaryotic messenger RNAs in translation and its investigation using antisense technologies. <b>1994</b> , 48, 181-238		14
407	Biological availability and nuclease resistance extend the in vitro activity of a phosphorothioate-3'-hydroxypropylamine oligonucleotide. <i>Nucleic Acids Research</i> , <b>1994</b> , 22, 977-86	20.1	9
406	Patterns of intracellular compartmentalization, trafficking and acidification of 5' fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. <i>Nucleic Acids Research</i> , <b>1994</b> , 22, 4268-75	20.1	118
405	Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. <b>1994</b> , 4, 35-42		79
404	Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. <b>1994</b> , 103, 569-75		77
403	Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. <b>1994</b> , 38, 831-6		83
402	Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses. <b>1994</b> , 139, 97-109		5
401	Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat. <b>1994</b> , 14, 475-86		56
400	Synthesis and physical properties of sulfonamide-containing oligonucleotides. <b>1994</b> , 4, 1071-1076		18
399	Oligonucleotides in the treatment of leukemia. <b>1994</b> , 12, 9-14		24
398	Specificity in splicing. <b>1994</b> , 16, 771-4		13
397	Suppression of ischemia-induced fos expression and AP-1 activity by an antisense oligodeoxynucleotide to c-fos mRNA. <b>1994</b> , 36, 566-76		67
396	Stereokontrollierte Synthese von Oligonucleosidphosphorothioaten. <b>1994</b> , 106, 747-761		13
395	Transport of oligonucleotides across natural and model membranes. <b>1994</b> , 1197, 95-108		78

394	DNA uptake stimulating protein from <i>Neurospora crassa</i> enhances DNA and oligonucleotide uptake also in mammalian cells. <b>1994</b> , 1219, 314-20	3
393	ANTISENSE oligonucleotides: a new tool in neuroscience. <b>1994</b> , 21, 935-44	31
392	Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. <b>1994</b> , 85, 775-9	74
391	Triple-helix formation interferes with the transcription and hinged DNA structure of the interferon-inducible 6-16 gene promoter. <b>1994</b> , 220, 493-503	14
390	The interaction of membrane DNA-binding protein with DNA. <b>1994</b> , 311, 353-358	
389	Vaccine, Drug, Antisense, and Third-Strand Therapies. <b>1994</b> , 385-412	
388	Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. <b>1994</b> , 1196, 201-8	60
387	Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene <i>mdr1</i> in MDR cancer cells. <b>1994</b> , 352, 380-4	35
386	Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. <b>1994</b> , 25, 13-25	35
385	Antisense Technology. <b>1994</b> , 1, 405-409	3
384	Antisense treatment of viral infection. <b>1994</b> , 44, 267-303	12
383	Antisense c-myc oligonucleotide cellular uptake and activity. <b>1994</b> , 4, 155-63	45
382	Use of partially phosphorothioated "antisense" oligodeoxynucleotides for sequence-dependent modulation of hematopoiesis in culture. <b>1994</b> , 4, 173-83	35
381	Inhibition of proopiomelanocortin expression by an oligodeoxynucleotide complementary to beta-endorphin mRNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1994</b> , 91, 8072-6	11.5 29
380	Retroviral inhibition by antisense oligonucleotides determined by intracellular stability. <b>1994</b> , 4, 207-10	8
379	Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. <b>1994</b> , 4, 43-52	84
378	Cellular pharmacology and protein binding of phosphoromonothioate and phosphorodithioate oligodeoxynucleotides: a comparative study. <b>1994</b> , 4, 269-78	22
377	Influence of base composition on membrane binding and cellular uptake of 10-mer phosphorothioate oligonucleotides in Chinese hamster ovary (CHRC5) cells. <b>1994</b> , 4, 211-5	22

376	Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1994</b> , 91, 10460-4	11.5	156
375	Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by <i>Schistosoma mansoni</i> . <b>1995</b> , 5, 123-9		12
374	Immunologic consequences of nucleic acid therapy. <b>1995</b> , 5, 219-25		13
373	Digoxigenin-labeled phosphorothioate oligonucleotides: a new tool for the study of cellular uptake. <b>1995</b> , 5, 193-201		11
372	Phosphorothioate oligonucleotides cause degradation of secretory but not intracellular serglycin proteoglycan core protein in a sequence-independent manner in human megakaryocytic tumor cells. <b>1995</b> , 5, 59-65		10
371	Section Review: Biologicals & Immunologicals: Antisense oligonucleotides: Rational drug design for genetic pharmacology. <b>1995</b> , 4, 799-821		12
370	Towards a new concept of gene inactivation: specific RNA cleavage by endogenous ribonuclease P. <b>1995</b> , 1, 215-65		12
369	Cellular uptake of oligodeoxyribonucleoside methylphosphonates. <b>1995</b> , 5, 251-9		28
368	CpG DNA: a pathogenic factor in systemic lupus erythematosus?. <b>1995</b> , 15, 284-92		145
367	Antisense vasopressin oligonucleotides: uptake, turnover, distribution, toxicity and behavioral effects. <b>1995</b> , 7, 419-28		25
366	Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. <b>1995</b> , 47, 1462-9		102
365	Section ReviewOncologic, Endocrine & Metabolic: Gene Therapy Strategies for Cancer. <b>1995</b> , 4, 487-514		
364	Ribozyme-mediated RNA degradation in nuclei suspension. <i>Nucleic Acids Research</i> , <b>1995</b> , 23, 2223-8	20.1	51
363	Advances in cancer gene therapy. <b>1995</b> , 32, 289-341		20
362	G Protein-Coupled Receptors. <i>Molecular Biology Intelligence Unit</i> , <b>1995</b> ,		32
361	Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. <b>1995</b> , 5, 213-7		37
360	High-affinity triple helix formation by synthetic oligonucleotides at a site within a selectable mammalian gene. <b>1995</b> , 34, 7243-51		62
359	In vivo antisense approaches to the role of immediate early gene expression in the brain. <b>1995</b> , 59, 151-62		21



358	ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. <b>1995</b> , 59, 207-14		62
357	Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23/nucleolin. <b>1995</b> , 366, 146-50		52
356	Immunological properties of bacterial DNA. <b>1995</b> , 772, 152-63		34
355	Potential of Antisense Technology in the Treatment of Immunological Disorders. <b>1995</b> , 4, 169-179		3
354	Renal uptake of an 18-mer phosphorothioate oligonucleotide. <b>1995</b> , 48, 1226-32		60
353	Antisense oligonucleotides in the study of neuroendocrine systems. <b>1995</b> , 7, 493-500		20
352	Identification of two oligodeoxyribonucleotide binding proteins on plasma membranes of human cell lines. <b>1996</b> , 51, 431-6		28
351	Antisense oncogene and tumor suppressor gene therapy of cancer. <b>1996</b> , 74, 191-204		18
350	Immune activation by bacterial DNA: a new genetic code. <b>1996</b> , 5, 303-10		273
349	The influence of polarized epithelial (Caco-2) cell differentiation on the cellular binding of phosphodiester and phosphorothioate oligonucleotides. <b>1996</b> , 6, 197-206		14
348	Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus. <b>1996</b> , 40, 1670-5		18
347	Antisense approach to restenosis. <b>1996</b> , 60, 1-9		2
346	Antisense Oligonucleotides: Considerations for Lymphoma Therapy. <b>1996</b> , 1, 53-7		1
345	Development of antisense and antigene oligonucleotide analogs. <b>1996</b> , 52, 261-91		24
344	5 Discovery and Characterization of a Thrombin Aptamer Selected from a Combinatorial ssDNA Library.		
343	In vivo suppression of the renal Na <sup>+</sup> /Pi cotransporter by antisense oligonucleotides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1996</b> , 93, 4903-6	11.5	38
342	Uptake and distribution of fluorescein-labeled D2 dopamine receptor antisense oligodeoxynucleotide in mouse brain. <b>1996</b> , 7, 13-28		27
341	Polyacrylic acid mediated ocular delivery of ribozymes. <i>Journal of Controlled Release</i> , <b>1996</b> , 38, 167-175	11.7	11

340	Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet?. <i>Journal of Controlled Release</i> , <b>1996</b> , 41, 99-119	11.7	69
339	Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. <i>Journal of Controlled Release</i> , <b>1996</b> , 41, 121-130	11.7	28
338	Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial Caco-2 cells. <b>1996</b> , 13, 1028-37		28
337	Antisense oligodeoxynucleotides: Internalization, compartmentalization and non-sequence specificity. <b>1996</b> , 4, 41-50		18
336	Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. <b>1996</b> , 33, 11-20		24
335	Anti-sense and gene therapy approaches to the treatment of lymphomas. <b>1996</b> , 9, 819-34		3
334	Binding of nucleosomes to a cell surface receptor: redistribution and endocytosis in the presence of lupus antibodies. <b>1996</b> , 26, 472-86		77
333	Antisense approaches to the gene therapy of cancer--RecnacP <b>1996</b> , 15, 287-99		33
332	Antisense Oligonucleotides: New Tools for the Study of Brain Function. <b>1996</b> , 2, 79-82		10
331	Repression of transforming growth factor beta 1 protein by antisense oligonucleotide-induced increase of adrenal cell differentiated functions. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 11027-33	5.4	17
330	Hairpin, dumbbell, and single-stranded phosphodiester oligonucleotides exhibit identical uptake in T lymphocyte cell lines. <b>1996</b> , 6, 157-63		5
329	Interaction of oligodeoxynucleotides with mammalian cells. <b>1996</b> , 6, 185-95		38
328	Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data. <b>1996</b> , 6, 215-20		3
327	Detection of covalent triplex within human cells. <i>Nucleic Acids Research</i> , <b>1996</b> , 24, 4210-6	20.1	35
326	Role of Long Form PDGF A Chain in the Growth of Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats. <b>1997</b> ,		
325	Controversies in the cellular pharmacology of oligodeoxynucleotides. <b>1997</b> , 7, 207-9		18
324	Inhibition of troponin C production without affecting other muscle protein synthesis by the antisense oligodeoxynucleotide. <b>1997</b> , 7, 31-8		4
323	Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. <b>1997</b> , 7, 483-93		52

322	Drug Toxicity in Embryonic Development I. <i>Handbook of Experimental Pharmacology</i> , <b>1997</b> ,	3.2	1
321	Cellular uptake properties of a 2Pamino/2PO-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. <b>1997</b> , 7, 319-26		21
320	Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. <b>1997</b> , 89, 124-33		49
319	Polyethylelimine Masks Mitogenic Effect of DNA. <b>1997</b> , 16, 1883-1891		1
318	Antisense oligodeoxynucleotide complementary to platelet-derived growth factor A-chain messenger RNA inhibits the arterial proliferation in spontaneously hypertensive rats without altering their blood pressures. <b>1997</b> , 15, 1123-36		25
317	Targeted Delivery of Antisense Oligodeoxynucleotides by LPDII. <b>1997</b> , 7, 63-75		17
316	Oligonucleotides and polynucleotides as biologically active compounds. <b>1997</b> , 57, 95-143		13
315	Centrally administered oligodeoxynucleotides in rats: occurrence of non-specific effects. <b>1997</b> , 331, 97-107		40
314	Antisense inhibition of angiotensinogen in hepatoma cell culture is enhanced by cationic liposome delivery. <b>1997</b> , 232, 794-9		10
313	Role of long-form PDGF A-chain in the growth of vascular smooth muscle cells from spontaneously hypertensive rats. <b>1997</b> , 10, 1117-24		26
312	Rapid sequence-independent cellular response to oligodeoxynucleotides. <b>1997</b> , 400, 267-70		1
311	Antisense oligonucleotides in neuroendocrinology: enthusiasm and frustration. <b>1997</b> , 31, 363-78		15
310	On the role of c-fos expression in striatal transmission. The antisense oligonucleotide approach. <b>1997</b> , 31, 425-36		8
309	Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo. <b>1997</b> , 75, 82-7		17
308	Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. <b>1997</b> , 3, 414-20		222
307	Antisense approaches for investigating mechanisms of abnormal development. <b>1997</b> , 396, 175-93		11
306	Therapeutic potential and mechanism of action of oligonucleotides and ribozymes. <b>1997</b> , 62, 11-22		19
305	Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules. <b>1997</b> , 31, 171-80		6

304	DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors. <i>Molecular and Cellular Biochemistry</i> , <b>1997</b> , 172, 199-211	4.2	3
303	Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems. <b>1997</b> , 71, 45-53		29
302	Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <b>1997</b> , 27, 1671-9		370
301	Nephritogenic T cells use granzyme C as a cytotoxic mediator. <b>1997</b> , 27, 2302-9		16
300	Antisense therapy for lymphomas. <b>1997</b> , 15, 3-11		19
299	Targeted antisense modulation of inflammatory cytokine receptors. <b>1997</b> , 55, 72-81		6
298	Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. <b>1998</b> , 15, 1540-5		37
297	Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression. <b>1998</b> , 87, 616-25		9
296	The influence of base sequence on the immunological properties of defined oligonucleotides. <b>1998</b> , 40, 199-208		29
295	Lipid fusion in oligonucleotide and gene delivery with cationic lipids. <b>1998</b> , 34, 37-49		76
294	Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. <i>Journal of Controlled Release</i> , <b>1998</b> , 53, 137-43	11.7	113
293	Antisense oligonucleotides: strategies for delivery. <b>1998</b> , 1, 377-386		17
292	Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes. <b>1998</b> , 290, 119-25		20
291	Growth inhibition of pancreatic tumor cells by modified antisense oligodeoxynucleotides. <b>1998</b> , 383, 269-75		5
290	Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides. <b>1998</b> , 6, 1025-32		10
289	Different frequency of gene targeting events by the RNA-DNA oligonucleotide among epithelial cells. <b>1998</b> , 111, 1172-7		46
288	Antisense inhibition of striatal GABAA receptor proteins decreases GABA-stimulated chloride uptake and increases cocaine sensitivity in rats. <b>1998</b> , 57, 310-20		16
287	Bacterial DNA as immune cell activator. <b>1998</b> , 6, 496-500		108

286	Autoreactive B cell regulation: peripheral induction of developmental arrest by lupus-associated autoantigens. <b>1998</b> , 8, 209-19		91
285	Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides. <b>1998</b> , 425, 91-6		19
284	Different effects of an oligonucleotide uptake stimulating protein on leukemic cells in their primitive and differentiated state. <b>1998</b> , 430, 241-5		1
283	Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice. <b>1998</b> , 8, 451-8		32
282	Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides. <i>Nucleic Acids Research</i> , <b>1998</b> , 26, 5310-7	20.1	69
281	Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. <b>1998</b> , 5, 149-62		41
280	In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages. <b>1998</b> , 41, 4224-31		22
279	The CpG motif: implications for clinical immunology. <b>1998</b> , 10, 341-6		13
278	Inhibition of human angiogenin by DNA aptamers: nuclear colocalization of an angiogenin-inhibitor complex. <b>1998</b> , 37, 6857-63		44
277	Interaction of human plasma membrane proteins and oligodeoxynucleotides. <b>1998</b> , 55, 1221-7		5
276	Sequence dependency of the internalization and distribution of phosphorothioate oligonucleotides in vascular smooth muscle cells. <b>1998</b> , 55, 1465-73		7
275	Cellular uptake properties of oligonucleotides in LLC-PK1 renal epithelial cells. <b>1998</b> , 8, 67-73		14
274	Uncoordinated inhibition of gene expression for muscle proteins by a troponin T antisense oligodeoxynucleotide. <b>1998</b> , 8, 237-47		3
273	Enhancement of anti-herpetic activity of antisense phosphorothioate oligonucleotides 5' end modified with geraniol. <b>1998</b> , 5, 261-73		9
272	Stabilization of slow troponin C polypeptide compensates for its reduced synthesis in antisense oligodeoxynucleotide-treated cells. <i>Nucleic Acids Research</i> , <b>1998</b> , 26, 4765-70	20.1	3
271	Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. <i>Nucleic Acids Research</i> , <b>1998</b> , 26, 2016-23	20.1	104
270	Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells. <b>1998</b> , 9, 253-62		19
269	Identification and characterization of a cell membrane nucleic acid channel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1998</b> , 95, 1921-6	11.5	115

268	Interactions between the Immune System and Gene Therapy Vectors: Bidirectional Regulation of Response and Expression. <b>1998</b> , 69, 353-409		45
267	Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset. <i>Blood</i> , <b>1998</b> , 91, 852-862	2.2	45
266	Nucleic Acid Therapeutics: State of the Art and Future Prospects. <i>Blood</i> , <b>1998</b> , 92, 712-736	2.2	216
265	Antisense oligonucleotides. <b>1998</b> , 6, 84-8		10
264	Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. <b>1998</b> , 53, 262-9		54
263	Effects of antisense oligonucleotide to iNOS on hemodynamic and vascular changes induced by LPS. <b>1998</b> , 275, H1078-83		8
262	Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide. <b>1999</b> , 43, 2689-96		29
261	Suppression of postischemic hippocampal nerve growth factor expression by a c-fos antisense oligodeoxynucleotide. <b>1999</b> , 19, 1335-44		50
260	The 3rd Annual NIH Symposium on Therapeutic Oligonucleotides. Bethesda, Maryland, USA. December 4, 1998. Abstracts. <b>1999</b> , 9, 359-431		6
259	Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. <i>Nucleic Acids Research</i> , <b>1999</b> , 27, 2315-24	20.1	59
258	Blood Cell Biochemistry. <i>Blood Cell Biochemistry</i> , <b>1999</b> ,		1
257	Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 31047-54		217
256	The influence of lipofectin on the in vitro stimulation of murine spleen cells by bacterial DNA and plasmid DNA vectors. <b>1999</b> , 19, 1219-26		11
255	Delivery of antisense oligonucleotides and plasmid DNA with various carrier agents. <b>1999</b> , 9, 497-505		23
254	Nucleic acid biotechnology. <b>1999</b> , 1, 265-97		39
253	Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 6411-6	11.5	109
252	Decreased bone resorption, osteoclast differentiation, and expression of vacuolar H <sup>+</sup> -ATPase in antisense DNA-treated mouse metacarpal and calvaria cultures ex vivo. <b>1999</b> , 9, 155-69		7
251	A pressure-mediated nonviral method for efficient arterial gene and oligonucleotide transfer. <b>1999</b> , 10, 2355-64		23

250	Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. <b>1999</b> , 17, 583-7	49
249	Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. <b>1999</b> , 126, 537-50	186
248	Mechanisms and therapeutic applications of immune stimulatory CpG DNA. <b>1999</b> , 84, 113-20	58
247	Oligonucleotide therapeutics for hematologic disorders. <b>1999</b> , 1489, 85-96	18
246	Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. <b>1999</b> , 1489, 45-52	58
245	Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. <b>1999</b> , 1489, 107-16	113
244	Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture. <b>1999</b> , 58, 95-107	31
243	Omega-6 polyunsaturated fatty acid-stimulated cellular internalization of phosphorothioate oligodeoxynucleotides: evidence for protein kinase C-zeta dependency. <b>1999</b> , 58, 411-23	4
242	Direct Immunologic activities of CpG DNA and implications for gene therapy. <b>1999</b> , 1, 56-63	9
241	Presence of pituitary specific transcription factor pit-1 in the rat brain: Intracerebroventricular administration of antisense pit-1 oligodeoxynucleotide decreases brain prolactin mRNA level. <b>1999</b> , 3, 311-317	
240	A novel <sup>111</sup> In-labeled antisense DNA probe with multi-chelating sites (MCS-probe) showing high specific radioactivity and labeling efficiency. <b>1999</b> , 26, 17-21	14
239	Evaluation of aminoalkylmethacrylate nanoparticles as colloidal drug carrier systems. Part II: characterization of antisense oligonucleotides loaded copolymer nanoparticles. <b>1999</b> , 48, 1-12	45
238	Transport of CSF antibodies to Galpha subunits across neural membranes requires binding to the target protein and protein kinase C activity. <b>1999</b> , 65, 151-66	8
237	Myr+-Gi2 alpha and Go alpha subunits restore the efficacy of opioids, clonidine and neurotensin giving rise to antinociception in G-protein knock-down mice. <b>1999</b> , 38, 1861-73	16
236	Specific inhibition of human telomerase activity by transfection reagent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells. <b>1999</b> , 454, 312-6	15
235	A fluorescent radioiodinated oligonucleotidic photoaffinity probe for protein labeling: synthesis and photolabeling of thrombin. <i>Bioconjugate Chemistry</i> , <b>1999</b> , 10, 56-61	6.3 12
234	Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells. <b>1999</b> , 38, 13473-9	34
233	Monitoring antisense oligodeoxynucleotide activity in hematopoietic cells. <b>1999</b> , 17, 219-30	28

232	Gene therapy and vascular disease. <b>1999</b> , 46, 85-150		12
231	Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. <b>2000</b> , 165, 3631-9		60
230	Inhibition of Ras p21 synthesis by antisense undecamers with uniform and specifically arranged phosphorothioate linkages. <b>2000</b> , 11, 181-91		4
229	Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. <b>2000</b> , 2, 76-88		180
228	Inhibition of Lncap prostate cancer cells by means of androgen receptor antisense oligonucleotides. <i>Cancer Gene Therapy</i> , <b>2000</b> , 7, 997-1007	5-4	138
227	Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. <b>2000</b> , 19, 131-47		71
226	Novel non-endocytic delivery of antisense oligonucleotides. <b>2000</b> , 44, 35-49		75
225	Alternative interpretations of the oligonucleotide transport literature: insights from nature. <b>2000</b> , 44, 59-70		17
224	Delivery systems for antisense oligonucleotides. <b>2000</b> , 87, 255-77		81
223	Nuclear transport of oligonucleotides in HepG2-cells mediated by protamine sulfate and negatively charged liposomes. <b>2000</b> , 17, 1206-11		19
222	Peptide Conjugates of Oligonucleotides As Enhanced Antisense Agents. <b>2000</b> , 34, 852-859		16
221	Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. <b>2000</b> , 27, 1700-7		59
220	A human gene coding for a membrane-associated nucleic acid-binding protein. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 33655-62	5-4	41
219	Chemistry of Antisense Oligonucleotides. <b>2000</b> , 261-347		3
218	A cationic derivative of amphotericin B as a novel delivery system for antisense oligonucleotides. <b>2000</b> , 10, 177-84		11
217	Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. <b>2000</b> , 10, 263-74		38
216	Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. <b>2000</b> , 10, 35-44		38
215	Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of HepG2 cells. <i>Nucleic Acids Research</i> , <b>2000</b> , 28, 868-74	20.1	23



214	Intratumoral injection of naked DNA. <b>2000</b> , 35, 313-21	1
213	Gene Therapy of Cancer. <b>2000</b> ,	1
212	Development of efficient transient transfection systems for introducing antisense oligonucleotides into human epithelial skin cells. <b>2000</b> , 54, 306-11	7
211	Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent, FuGENE6, in HeLa cells. <b>2000</b> , 10, 87-96	11
210	Inhibition of HIV-1 replication by a new type of circular dumbbell RNA/DNA chimeric oligonucleotides. <b>2000</b> , 270, 953-60	9
209	Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. <b>2000</b> , 279, 158-61	17
208	Enhanced antisense efficacy of oligonucleotides adsorbed to monomethylaminoethylmethacrylate methylmethacrylate copolymer nanoparticles. <b>2000</b> , 49, 203-10	22
207	Cellular delivery of antisense oligonucleotides. <b>2000</b> , 50, 101-19	103
206	Antisense oligonucleotides in cancer: recent advances. <b>2000</b> , 13, 195-216	16
205	Immunostimulatory sequence up-modulate the interaction between immunoglobulins and plasmid DNA at acidic pH. <b>2001</b> , 19, 3051-7	1
204	The Rossmann fold of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a nuclear docking site for antisense oligonucleotides containing a TAAAT motif. <b>2001</b> , 1530, 32-46	11
203	Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 42-47	11.5 324
202	P-Chiral Oligonucleotides. Effect of Configuration at Phosphorus on Transport of Tetra(thymidine Methylphosphonate)s Across Organic Liquid Membrane. <b>2001</b> , 66, 912-922	1
201	The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. <b>2001</b> , 103, 226-34	65
200	Antisense oligodeoxynucleotide-induced suppression of basal forebrain NMDA-NR1 subunits selectively impairs visual attentional performance in rats. <b>2001</b> , 14, 103-17	17
199	Nanoparticulate systems for the delivery of antisense oligonucleotides. <b>2001</b> , 47, 99-112	163
198	Antisense therapy of influenza. <b>2001</b> , 13, 61-9	21
197	Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. <b>2001</b> , 167, 66-74	110

196	Slow accumulation of plasmid in muscle cells: supporting evidence for a mechanism of DNA uptake by receptor-mediated endocytosis. <b>2001</b> , 4, 317-23		75
195	The direction of ribonucleases H by antisense oligodeoxynucleotides. <b>2001</b> , 160, 157-82		4
194	Antisense inhibition of Flk-1 by oligonucleotides composed of 2Pdeoxy-2Pfluoro-beta-D-arabino- and 2Pdeoxy-nucleosides. <b>2002</b> , 80, 951-61		4
193	Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. <b>2002</b> , 12, 289-99		100
192	Reaction of keratinocytes to exogenous DNA. <b>2002</b> , 172, 86-95		5
191	Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for non-conventional intracellular trafficking. <i>Nucleic Acids Research</i> , <b>2002</b> , 30, 1512-21	20.1	26
190	Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. <i>Nucleic Acids Research</i> , <b>2002</b> , 30, 3632-41	20.1	32
189	Liposome-mediated delivery of oligodeoxynucleotides in vivo. <b>2002</b> , 9, 169-80		44
188	Genetics of Endocrine-Behavior Interactions. <b>2002</b> , 263-XXXV		
187	Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. <i>Bioconjugate Chemistry</i> , <b>2002</b> , 13, 1220-5	6.3	44
186	CpG motifs in bacterial DNA and their immune effects. <b>2002</b> , 20, 709-60		2122
185	Antisense therapy: recent advances and relevance to prostate cancer. <b>2002</b> , 1, 20-30		8
184	Oligodeoxynucleotides induce brain inflammation in rats when infused intracerebroventricularly. <b>2002</b> , 322, 107-10		5
183	Genetically engineered mice for studies of stress-related clinical conditions. <b>2002</b> , 36, 53-76		38
182	From molecular biology to nanotechnology and nanomedicine. <b>2002</b> , 65, 123-38		159
181	Nucleic-acid therapeutics: basic principles and recent applications. <b>2002</b> , 1, 503-14		412
180	Induction of acute phase response genes in keratinocytes following exposure to oligodeoxynucleotides. <b>2002</b> , 80, 377-83		9
179	The role of extracellular DNA in the stability and variability of cell genomes. <b>2002</b> , 382, 31-4		5

178	Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts. <b>2003</b> , 30, 1273-80		14
177	Monitoring liposome-mediated delivery and fate of an antisense drug in cell extracts and in single cells by capillary electrophoresis with laser-induced fluorescence. <b>2003</b> , 24, 1054-62		17
176	Innovations in oligonucleotide drug delivery. <b>2003</b> , 92, 1559-73		64
175	Optimization of functional efficacy of phosphorothioate-modified oligonucleotides in a human CD8+ T-cell ex vivo expansion model. <b>2003</b> , 58, 462-70		2
174	The future of antisense therapy: combination with anticancer treatments. <b>2003</b> , 22, 6579-88		64
173	Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. <i>Bioconjugate Chemistry</i> , <b>2003</b> , 14, 738-47	6.3	138
172	Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells. <b>2003</b> , 14, 849-60		30
171	Polyalkylcyanoacrylate Nanospheres and Nanocapsules for the Delivery of Antisense Oligonucleotides. <b>2003</b> , 24, 439-452		4
170	Ten years of antisense inhibition of brain G-protein-coupled receptor function. <b>2003</b> , 42, 123-42		21
169	Cellular uptake and metabolism of DNA frayed wires. <b>2003</b> , 42, 11427-33		11
168	In vivo imaging with oligonucleotides for diagnosis and drug development. <b>2003</b> , 52 Suppl 4, iv40-7		36
167	Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner. <b>2003</b> , 170, 2367-73		31
166	A1 receptor and adenosinergic homeostatic regulation of sleep-wakefulness: effects of antisense to the A1 receptor in the cholinergic basal forebrain. <b>2003</b> , 23, 4278-87		149
165	Aspects of Antisense Oligodeoxynucleotide, Ribozyme, DNA Enzyme and RNAi Design. <b>2004</b> , 4, 1-15		1
164	Peptide conjugates for chromosomal gene targeting by triplex-forming oligonucleotides. <i>Nucleic Acids Research</i> , <b>2004</b> , 32, 6595-604	20.1	37
163	Binding features of BCL2-targeted oligodeoxynucleotides with K562 cells. <b>2004</b> , 23, 943-51		0
162	B lymphocytes as antigen-presenting cell-based genetic vaccines. <b>2004</b> , 199, 264-78		34
161	Spontaneous transgenesis of human B lymphocytes. <b>2004</b> , 11, 42-51		20

160	A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. <i>Journal of Controlled Release</i> , <b>2004</b> , 99, 139-55	11.7	76
159	"Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. <b>2004</b> , 56, 931-46		182
158	Poly(L-lysine)-modified silica nanoparticles for the delivery of antisense oligonucleotides. <b>2004</b> , 39, 179-87		66
157	Oligonucleotide delivery to tumours using macromolecular carriers. <b>2004</b> , 40, 113-22		15
156	Isolation of nucleic acid binding proteins: an approach for isolation of cell surface, nucleic acid binding proteins. <b>2004</b> , 1022, 239-43		7
155	Cyclodextrins and oligonucleotide delivery to solid tumours. <b>2004</b> , 12, 1-9		11
154	Enhancement of the Antisense Effect of Polysaccharide-Polynucleotide Complexes by Preventing the Antisense Oligonucleotide from Binding to Proteins in the Culture Medium. <b>2004</b> , 77, 1101-1110		22
153	The uptake of a fluorescently labelled antisense oligonucleotide in vitro and in vivo. <b>2005</b> , 147, 48-54		2
152	Therapeutic potential of nanoparticulate systems for macrophage targeting. <b>2005</b> , 26, 7260-75		205
151	Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle. <b>2005</b> , 27, 488-93		18
150	[Antisense therapy in oncology: present situation]. <b>2005</b> , 29, 269-82		
149	Intracellular distribution of NFkappaB decoy and its inhibitory effect on TNFalpha production by LPS stimulated RAW 264.7 cells. <i>Journal of Controlled Release</i> , <b>2005</b> , 107, 373-82	11.7	9
148	Binding and transfer of an oligodeoxynucleotide containing the translation initiation site of the BCL2 mRNA into K562 cells. <b>2005</b> , 39, 210-217		
147	Cholesterol conjugated oligonucleotide and LNA: a comparison of cellular and nuclear uptake by Hep2 cells enhanced by streptolysin-O. <i>Molecular and Cellular Biochemistry</i> , <b>2005</b> , 276, 61-9	4.2	16
146	Oligonucleotides as radiopharmaceuticals. <b>2005</b> , 1-34		3
145	Nanotechnology on duty in medical applications. <b>2005</b> , 6, 17-33		169
144	Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. <b>2005</b> , 2, 3-28		62
143	Pigpen is a cellular binding protein of therapeutic oligonucleotides. <b>2005</b> , 7, 186-94		4

142	Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides. <b>2005</b> , 89, 2286-95	18
141	Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo. <b>2006</b> , 8, R103	14
140	Enhanced cellular binding of concatemeric oligonucleotide complexes. <b>2006</b> , 1758, 413-8	7
139	Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. <b>2006</b> , 60, 607-20	72
138	On the role of methacrylic acid copolymers in the intracellular delivery of antisense oligonucleotides. <b>2006</b> , 63, 1-10	42
137	c-Myc and downstream targets in the pathogenesis and treatment of cancer. <b>2006</b> , 1, 305-26	29
136	Qualitative and quantitative characteristics of the extracellular DNA delivered to the nucleus of a living cell. <b>2006</b> , 6, 23	7
135	Proteins involved in binding and cellular uptake of nucleic acids. <b>2006</b> , 71, 583-96	18
134	An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells. <b>2006</b> , 2, 113-20	45
133	TLR9 and the recognition of self and non-self nucleic acids. <b>2006</b> , 1082, 31-43	76
132	Structural variation of cationic lipids: minimum requirement for improved oligonucleotide delivery into cells. <i>Journal of Controlled Release</i> , <b>2006</b> , 110, 444-456	11.7 20
131	Antisense applications for biological control. <b>2006</b> , 98, 14-35	41
130	Ex vivo programming of antigen-presenting B lymphocytes: considerations on DNA uptake and cell activation. <b>2006</b> , 25, 83-97	6
129	Nucleic acid drugs in the clinic. <b>2007</b> , 2, 321-33	4
128	Oligonucleotides: Superspecific Ligands for Targeting Nucleic Acids and Proteins and Development of Molecular Devices. <b>2007</b> , 89-147	
127	Natural human gene correction by small extracellular genomic DNA fragments. <b>2007</b> , 6, 2293-301	5
126	Delivery of 5-aza-2Pdeoxycytidine to cells using oligodeoxynucleotides. <b>2007</b> , 67, 6400-8	183
125	Therapeutic applications of antisense oligonucleotides in asthma and allergy. <b>2007</b> , 1, 171-5	1

124	Bioconjugation of oligonucleotides for treating liver fibrosis. <b>2007</b> , 17, 349-404		21
123	State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. <b>2008</b> , 364, 237-48		99
122	Characterization of bacterial DNA binding to human neutrophil surface. <b>2008</b> , 88, 926-37		20
121	What happens to the DNA vaccine in fish? A review of current knowledge. <b>2008</b> , 25, 1-18		113
120	Radiolabelled oligonucleotides for imaging of gene expression with PET. <i>Current Medicinal Chemistry</i> , <b>2009</b> , 16, 4445-61	4-3	29
119	Oligonucleotide Duplexes with Tethered Photoreactive Ruthenium(II) Complexes: Influence of the Ligands and Their Linker on the Photoinduced Electron Transfer and Crosslinking Processes of the Two Strands. <b>2009</b> , 2009, 524-532		20
118	Specific inhibition of epithelial Na <sup>+</sup> channels by antisense oligonucleotides for the treatment of Na <sup>+</sup> hyperabsorption in cystic fibrosis. <b>2009</b> , 11, 813-23		10
117	Growth inhibition of SK-MEL-30 human melanoma cells by antisense c-myc oligonucleotides delivered by poly(N-isopropylacrylamide)/ poly(ethyleneimine) copolymer. <b>2010</b> , 4, 284-90		2
116	Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. <b>2009</b> , 157, 179-94		76
115	Pericellular matrix formation alters the efficiency of intracellular uptake of oligonucleotides in osteosarcoma cells. <b>2009</b> , 152, 148-56		16
114	Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells. <b>2009</b> , 46, 1387-96		8
113	Oligonucleotide decoy to NF-kappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. <b>2009</b> , 60, 33-40		31
112	Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells. <b>2009</b> , 542, 351-61		1
111	Silica nanoparticles as a delivery system for nucleic acid-based reagents. <b>2009</b> , 19, 6308-6316		65
110	Cellular uptake of neutral phosphorodiamidate morpholino oligomers. <b>2009</b> , 10, 579-88		12
109	RNA- and DNA- Based Therapies for HuntingtonB Disease. <b>2010</b> , 225-253		2
108	Vehicles for oligonucleotide delivery to tumours. <b>2002</b> , 54, 3-27		60
107	Time-dependent thermocontrol of the hydrophilic and lipophilic properties of DNA oligonucleotide prodrugs. <b>2010</b> , Chapter 4, Unit 4.42.		1

106	Oligonucleotide delivery in cancer therapy. <b>2010</b> , 7, 1263-78	12
105	Nanoparticle mediated delivery of 2PO-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells. <b>2010</b> , 68, 346-54	25
104	The genetics of pain: implications for evaluation and treatment of spinal disease. <b>2010</b> , 10, 827-40	16
103	Radiolabeled oligonucleotides for antisense imaging. <b>2011</b> , 8, 604-614	22
102	Potential c-myc antisense oligonucleotide carriers: PCL/PEG/PEI and PLL/PEG/PEI. <b>2011</b> , 39, 143-54	7
101	Antisense 2PDeoxy, 2PFluoroarabino Nucleic Acids (2F-ANAs) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids. <b>2012</b> , 1, e43	48
100	Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation. <b>2012</b> , 47, 352-8	15
99	Oligodeoxynucleotides inhibit Toll-like receptor 3 mediated cytotoxicity and CXCL8 release in keratinocytes. <b>2012</b> , 21, 7-12	12
98	Traditional biochemical assays for studying toll-like receptor 9. <b>2013</b> , 34, 1-15	3
97	Circulating nucleic acids: possible inherited effects. <b>2013</b> , 110, 931-948	10
96	Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. <b>2013</b> , 8, e80458	44
95	Design and application of multifunctional DNA nanocarriers for therapeutic delivery. <b>2014</b> , 10, 1683-91	34
94	In situ tracking the intracellular delivery of antisense oligonucleotides by fluorescein doped silica nanoparticles. <b>2014</b> , 127, 43-50	6
93	Antisense gene inhibition by phosphorothioate antisense oligonucleotide in Arabidopsis pollen tubes. <b>2014</b> , 78, 516-26	13
92	The Biology of CNAPS. <b>2015</b> , 15-41	2
91	Sequence-specific transport of oligonucleotides into human endothelial cells. <b>2015</b> , 64, 1464-1469	
90	ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2PDeoxyuridine to Pancreatic Cancer. <i>Nucleic Acid Therapeutics</i> , <b>2015</b> , 25, 180-7	4.8 16
89	Ceruloplasmin is an endogenous protectant against kainate neurotoxicity. <b>2015</b> , 84, 355-372	14

88	Novel Natural Products: Therapeutic Effects in Pain, Arthritis and Gastro-intestinal Diseases. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , <b>2015</b> ,		7
87	Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization. <b>2016</b> , 3,		23
86	Properties of internalization factors contributing to the uptake of extracellular DNA into tumor-initiating stem cells of mouse Krebs-2 cell line. <b>2016</b> , 7, 76		10
85	Protein Kinase C- $\beta$ s a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells. <b>2016</b> , 24, 1117-1125		8
84	Evidence for cell-free nucleic acids as continuously arising endogenous DNA mutagens. <b>2016</b> , 793-794, 15-21		13
83	Antisense oligonucleotide delivery to cancer cell lines for the treatment of different cancer types. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , <b>2016</b> , 44, 1938-1948	6.1	12
82	Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer. <i>Journal of Controlled Release</i> , <b>2017</b> , 258, 1-9	11.7	28
81	Vector-independent transmembrane transport of oligodeoxyribonucleotides involves p38 mitogen activated protein kinase phosphorylation. <i>Scientific Reports</i> , <b>2017</b> , 7, 13571	4.9	1
80	Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors. <i>Cancer Gene Therapy</i> , <b>2017</b> , 24, 348-357	5.4	3
79	Nanoparticles as nucleic acid delivery vectors. <b>2017</b> , 13-42		1
78	Systemic delivery of the anticancer agent arenobufagin using polymeric nanomicelles. <i>International Journal of Nanomedicine</i> , <b>2017</b> , 12, 4981-4989	7.3	9
77	Ammonium and arsenic trioxide are potent facilitators of oligonucleotide function when delivered by gymnosin. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 3612-3624	20.1	4
76	Selection and Characterization of a DNA Aptamer Specifically Targeting Human HECT Ubiquitin Ligase WWP1. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	11
75	Double-Stranded DNA Fragments Bearing Unrepairable Lesions and Their Internalization into Mouse Krebs-2 Carcinoma Cells. <i>Nucleic Acid Therapeutics</i> , <b>2019</b> , 29, 278-290	4.8	3
74	Cell-surface-bound circulating DNA in the blood: Biology and clinical application. <i>IUBMB Life</i> , <b>2019</b> , 71, 1201-1210	4.7	11
73	Nucleic Acids as a Nature-Inspired Scaffold for Macromolecular Prodrugs of Nucleoside Analogues. <i>Advanced Science</i> , <b>2019</b> , 6, 1802095	13.6	3
72	Bottlebrush-architected poly(ethylene glycol) as an efficient vector for RNA interference in vivo. <i>Science Advances</i> , <b>2019</b> , 5, eaav9322	14.3	28
71	DNA delivery systems based on copolymers of poly (2-methyl-2-oxazoline) and polyethyleneimine: Effect of polyoxazoline moieties on the endo-lysosomal escape. <i>Journal of Applied Polymer Science</i> , <b>2020</b> , 137, 49400	2.9	8



70	Enhanced lysosome escape mediated by 1,2-dicarboxylic-cyclohexene anhydride-modified poly-L-lysine dendrimer as a gene delivery system. <i>Asian Journal of Pharmaceutical Sciences</i> , <b>2020</b> , 15, 759-776	9	6
69	Well-Defined DNA-Polymer Miktoarm Stars for Enzyme-Resistant Nanoflares and Carrier-Free Gene Regulation. <i>Bioconjugate Chemistry</i> , <b>2020</b> , 31, 530-536	6.3	5
68	Oligonucleotides Targeting DNA Repeats Downregulate Gene Expression in Huntington's Patient-Derived Neural Model System. <i>Nucleic Acid Therapeutics</i> , <b>2021</b> ,	4.8	2
67	Delivery. 167-210		2
66	Fluorescent Nucleoside Analogues as DNA Probes. <b>2003</b> , 151-175		18
65	Antisense Oligonucleotides as Potential Inhibitors of Gene Expression. <b>1993</b> , 272-300		2
64	Endogenous Expression Modification: Antisense Approaches. <i>Developments in Cardiovascular Medicine</i> , <b>1997</b> , 143-175		1
63	Possible Mechanisms of DNA Uptake in Skeletal Muscle. <b>1994</b> , 82-98		2
62	Regulation of Motor Behavior by Dopamine Receptor Subtypes. <b>1997</b> , 425-455		3
61	Design, Biological Properties and Delivery of Antisense Oligonucleotides. <b>1994</b> , 101-111		1
60	Immune Effects of Bacterial DNA and Their Possible Role in the Pathogenesis of Lupus. <b>1999</b> , 79-100		1
59	In Vitro Cellular Uptake, Distribution, and Metabolism of Oligonucleotides. <i>Handbook of Experimental Pharmacology</i> , <b>1998</b> , 103-140	3.2	4
58	Mechanism of action of CpG DNA. <i>Current Topics in Microbiology and Immunology</i> , <b>2000</b> , 247, 1-21	3.3	73
57	Responses of human B cells to DNA and phosphorothioate oligodeoxynucleotides. <i>Current Topics in Microbiology and Immunology</i> , <b>2000</b> , 247, 227-40	3.3	8
56	Targeted Gene Disruptions as Models of Abnormal Development. <i>Handbook of Experimental Pharmacology</i> , <b>1997</b> , 325-337	3.2	3
55	Oligonucleotide-Based Therapeutics of Human Malignancies. <i>Nucleic Acids and Molecular Biology</i> , <b>1994</b> , 298-326		8
54	Signal transduction induced by immunostimulatory CpG DNA. <i>Seminars in Immunopathology</i> , <b>2000</b> , 22, 97-105		8
53	Use of Antisense Oligodeoxynucleotides to Block Gene Expression in Central Nervous System. <i>Methods in Neurosciences</i> , <b>1994</b> , 22, 342-356		5

52	Antisense oligodeoxynucleotides as novel neuropharmacological tools for selective expression blockade in the brain. <b>1995</b> , 249-268		4
51	Mechanisms of inhibition of herpes simplex virus type 2 growth by 28-mer phosphorothioate oligodeoxycytidine. <i>Journal of Biological Chemistry</i> , <b>1990</b> , 265, 20172-20178	5-4	49
50	Oligodeoxynucleotides interact with recombinant CD4 at multiple sites.. <i>Journal of Biological Chemistry</i> , <b>1993</b> , 268, 18818-18823	5-4	69
49	Human T-cell leukemia virus type I tax transformation is associated with increased uptake of oligodeoxynucleotides in vitro and in vivo.. <i>Journal of Biological Chemistry</i> , <b>1992</b> , 267, 25881-25888	5-4	43
48	Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs.. <i>Journal of Biological Chemistry</i> , <b>1993</b> , 268, 5600-5604	5-4	39
47	Polynucleotide binding to macrophage scavenger receptors depends on the formation of base-quartet-stabilized four-stranded helices.. <i>Journal of Biological Chemistry</i> , <b>1993</b> , 268, 3546-3554	5-4	155
46	Chapter 10:Strategies for the Delivery of Oligonucleotides in vivo. <i>RSC Biomolecular Sciences</i> , <b>2008</b> , 226-240		2
45	Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 42-7	11.5	182
44	Antisense therapy for angioplasty restenosis. Some critical considerations. <i>Circulation</i> , <b>1995</b> , 92, 1981-93	6.7	59
43	Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty. <i>Circulation</i> , <b>1996</b> , 93, 772-80	16.7	16
42	Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. <i>Circulation</i> , <b>1997</b> , 95, 669-76	16.7	95
41	Reversible permeabilization. A novel technique for the intracellular introduction of antisense oligodeoxynucleotides into intact smooth muscle. <i>Circulation Research</i> , <b>1995</b> , 77, 220-30	15.7	48
40	Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. <i>Journal of Clinical Investigation</i> , <b>1995</b> , 95, 1814-23	15.9	241
39	Activation of human B cells by phosphorothioate oligodeoxynucleotides. <i>Journal of Clinical Investigation</i> , <b>1996</b> , 98, 1119-29	15.9	231
38	Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset. <i>Blood</i> , <b>1998</b> , 91, 852-862	2.2	4
37	Nucleic Acid Therapeutics: State of the Art and Future Prospects. <i>Blood</i> , <b>1998</b> , 92, 712-736	2.2	7
36	CpG-containing oligodeoxynucleotides induce TNF- $\alpha$ and IL-6 production but not degranulation from murine bone marrow-derived mast cells. <b>2001</b> , 69, 253-262		10
35	Gene, Oligonucleotide, and Ribozyme Therapy in the Eye. <b>2003</b> , 609-661		1

- 34 Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. *Journal of Cell Science*, **1992**, 103, 1249-1259 5.3 150
- 33 Canonical and non-canonical barriers facing anti-miR cancer therapeutics. *Current Medicinal Chemistry*, **2013**, 20, 3582-93 4.3 41
- 32 Antisense Knockdown of Dopamine Receptors. **2000**, 209-226
- 31 Uptake of DNA by Keratinocytes. **2001**, 81-94
- 30 Systematic Modulation of Immune Responses by CpG DNA. **2001**, 201-218
- 29 Signal transduction induced by immunostimulatory CpG DNA. **2001**, 97-105
- 28 Nucleic Acid Therapeutics. **2004**, 15-24
- 27 Controversies in the Cellular Pharmacology of Oligodeoxynucleotides. *Novartis Foundation Symposium*, 79-93 2
- 26 Small Nucleic Acid-Based Drugs: Successes and Pitfalls. **2008**, 193-221
- 25 Dosage Formulation. 1
- 24 High-Technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition. 1-38
- 23 Oncogene-targeted antisense oligonucleotides: tools for genetic analysis or new anticancer drugs?. *Cancer Biology and Medicine*, **1992**, 259-277
- 22 Antisense Nucleic Acids – Inhibition of Gene Expression via Triple Helix Formation. **1993**, 301-321
- 21 Extracellular nucleic acids as possible messengers of immune system morphogenetic function. Hypothesis about the exchange of regulatory molecules among the organism cells. *Biopolymers and Cell*, **1993**, 9, 5-12 0.3
- 20 Cellular Internalization of Oligodeoxynucleotides. **1994**, 180-192 1
- 19 G Protein-Coupled Receptors, Pathology and Therapeutic Strategies. *Molecular Biology Intelligence Unit*, **1995**, 135-169 1
- 18 DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors. **1997**, 199-211
- 17 Non-Specific Effects of Centrally Administered Oligonucleotides. *Perspectives in Antisense Science*, **1998**, 27-41

16	Rapid Onset of Antisense Effects: Evidence for A Close Link Between Gene Expression and Neuronal Activity. <i>Perspectives in Antisense Science</i> , <b>1998</b> , 43-59		0
15	Tissue Distribution, Cellular Uptake, and Intracellular Localization and Stability of Centrally Administered Oligonucleotides in the Brain: Implications for Behavioral and Physiological Effects of Antisense Oligonucleotides. <i>Perspectives in Antisense Science</i> , <b>1998</b> , 9-26		
14	A possible general mechanism of the signal transfer switching on the $\alpha$ / $\beta$ -interferons expression. 1. The local cell membrane deformation as the first induction stage. <i>Biopolymers and Cell</i> , <b>1998</b> , 14, 561-566	0.3	1
13	Oligonucleotides and Ribozymes. <b>1999</b> , 143-185		
12	The c-myb Protooncogene: A Novel Target for Human Gene Therapy. <b>1999</b> , 217-245		
11	Phosphorothioate Oligodeoxynucleotides as Inhibitors Of Gene Expression: Antisense and Non-Antisense Effects. <i>Perspectives in Antisense Science</i> , <b>1999</b> , 99-118		
10	Antisense Strategies to Leukemia. <i>Blood Cell Biochemistry</i> , <b>1999</b> , 269-292		
9	Critical Considerations and Future Directions. <i>Perspectives in Antisense Science</i> , <b>1999</b> , 163-179		
8	Therapeutic Effects of Ribonucleinate (Ribonucleotides) in Immuno-Inflammatory and Arthritic Diseases. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , <b>2015</b> , 70, 35-89		0
7	Nuclear Import of DNA. <b>2005</b> , 187-205		
6	Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study. <i>American Journal of Pathology</i> , <b>1995</b> , 147, 124-35	5.8	24
5	DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors. <i>Molecular and Cellular Biochemistry</i> , <b>1997</b> , 172, 199-211	4.2	
4	Blood Plasma Exosomes Contain Circulating DNA in Their Crown.. <i>Diagnostics</i> , <b>2022</b> , 12,	3.8	1
3	Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119,	11.5	1
2	NF- $\kappa$ B Decoy ODN-Loaded Poly lactic-co-glycolic Acid Nanospheres Inhibit Alveolar Ridge Resorption.		0
1	NF- $\kappa$ B Decoy ODN-Loaded Poly(Lactic-co-glycolic Acid) Nanospheres Inhibit Alveolar Ridge Resorption. <b>2023</b> , 24, 3699		0